Dermatitis Herpetiformis: An Update on Diagnosis, Disease Monitoring, and Management
Dermatitis herpetiformis (DH), Duhring disease, is caused by gluten sensitivity and affects 11.2 to 75.3 per 100,000 people in the United States and Europe with an incidence of 0.4 to 3.5 per 100,000 people per year. DH is characterized by a symmetrical blistering rash on the extensor surfaces with...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-08-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/57/8/843 |
| _version_ | 1797522993215176704 |
|---|---|
| author | Christopher N. Nguyen Soo-Jung Kim |
| author_facet | Christopher N. Nguyen Soo-Jung Kim |
| author_sort | Christopher N. Nguyen |
| collection | DOAJ |
| description | Dermatitis herpetiformis (DH), Duhring disease, is caused by gluten sensitivity and affects 11.2 to 75.3 per 100,000 people in the United States and Europe with an incidence of 0.4 to 3.5 per 100,000 people per year. DH is characterized by a symmetrical blistering rash on the extensor surfaces with severe pruritus. The diagnosis continues to be made primarily by pathognomonic findings on histopathology, especially direct immunofluorescence (DIF). Recently, anti-epidermal transglutaminase (TG3) antibodies have shown to be a primary diagnostic serology, while anti-tissue transglutaminase (TG2) and other autoantibodies may be used to support the diagnosis and for disease monitoring. Newly diagnosed patients with DH should be screened and assessed for associated diseases and complications. A gluten-free diet (GFD) and dapsone are still mainstays of treatment, but other medications may be necessary for recalcitrant cases. Well-controlled DH patients, managed by a dermatologist, a gastroenterologist, and a dietician, have an excellent prognosis. Our review comprehensively details the current diagnostic methods, as well as methods used to monitor its disease course. We also describe both the traditional and novel management options reported in the literature. |
| first_indexed | 2024-03-10T08:37:10Z |
| format | Article |
| id | doaj.art-8174de12dba54445a9bc0f7e1b248bbd |
| institution | Directory Open Access Journal |
| issn | 1010-660X 1648-9144 |
| language | English |
| last_indexed | 2024-03-10T08:37:10Z |
| publishDate | 2021-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-8174de12dba54445a9bc0f7e1b248bbd2023-11-22T08:36:57ZengMDPI AGMedicina1010-660X1648-91442021-08-0157884310.3390/medicina57080843Dermatitis Herpetiformis: An Update on Diagnosis, Disease Monitoring, and ManagementChristopher N. Nguyen0Soo-Jung Kim1School of Medicine, Baylor College of Medicine, Houston, TX 77030, USADepartment of Dermatology, Baylor College of Medicine, Houston, TX 77030, USADermatitis herpetiformis (DH), Duhring disease, is caused by gluten sensitivity and affects 11.2 to 75.3 per 100,000 people in the United States and Europe with an incidence of 0.4 to 3.5 per 100,000 people per year. DH is characterized by a symmetrical blistering rash on the extensor surfaces with severe pruritus. The diagnosis continues to be made primarily by pathognomonic findings on histopathology, especially direct immunofluorescence (DIF). Recently, anti-epidermal transglutaminase (TG3) antibodies have shown to be a primary diagnostic serology, while anti-tissue transglutaminase (TG2) and other autoantibodies may be used to support the diagnosis and for disease monitoring. Newly diagnosed patients with DH should be screened and assessed for associated diseases and complications. A gluten-free diet (GFD) and dapsone are still mainstays of treatment, but other medications may be necessary for recalcitrant cases. Well-controlled DH patients, managed by a dermatologist, a gastroenterologist, and a dietician, have an excellent prognosis. Our review comprehensively details the current diagnostic methods, as well as methods used to monitor its disease course. We also describe both the traditional and novel management options reported in the literature.https://www.mdpi.com/1648-9144/57/8/843dermatitis herpetiformisceliac diseasebullousautoimmunepruritisdisease monitoring |
| spellingShingle | Christopher N. Nguyen Soo-Jung Kim Dermatitis Herpetiformis: An Update on Diagnosis, Disease Monitoring, and Management Medicina dermatitis herpetiformis celiac disease bullous autoimmune pruritis disease monitoring |
| title | Dermatitis Herpetiformis: An Update on Diagnosis, Disease Monitoring, and Management |
| title_full | Dermatitis Herpetiformis: An Update on Diagnosis, Disease Monitoring, and Management |
| title_fullStr | Dermatitis Herpetiformis: An Update on Diagnosis, Disease Monitoring, and Management |
| title_full_unstemmed | Dermatitis Herpetiformis: An Update on Diagnosis, Disease Monitoring, and Management |
| title_short | Dermatitis Herpetiformis: An Update on Diagnosis, Disease Monitoring, and Management |
| title_sort | dermatitis herpetiformis an update on diagnosis disease monitoring and management |
| topic | dermatitis herpetiformis celiac disease bullous autoimmune pruritis disease monitoring |
| url | https://www.mdpi.com/1648-9144/57/8/843 |
| work_keys_str_mv | AT christophernnguyen dermatitisherpetiformisanupdateondiagnosisdiseasemonitoringandmanagement AT soojungkim dermatitisherpetiformisanupdateondiagnosisdiseasemonitoringandmanagement |